Lipocine Inc. filed its third-quarter 2026 financial results on November 5, 2026, reporting a net loss of $0.7 million for the quarter ended September 30, 2026, alongside a significant increase in revenue and an update on its BLOOM Phase 3 study for postpartum depression.
Key Highlights
- Net loss narrowed: Net loss was $0.7 million, or ($0.08) per diluted share, for Q3 2026, compared to a net loss of $3.2 million, or ($0.59) per diluted share, in Q3 2025.
- Revenue increased: Total revenue was $2.3 million for Q3 2026, up from $115,000 in Q3 2025, consisting of $2.1 million in license and collaboration revenue and $190,000 in TLANDO royalties.
- Cash position rose: Unrestricted cash, cash equivalents, and marketable investment securities were $21.5 million as of September 30, 2026, compared to $14.9 million at December 31, 2025.
- BLOOM study initiated: In September 2026, Lipocine announced the initiation of the BLOOM Phase 3 placebo-controlled outpatient study for postpartum depression, expected to enroll approximately 120 participants.
- TLANDO Canada approval: Health Canada approved TLANDO (testosterone undecanoate) capsules in September 2026, with partner Verity Pharma planning a Canadian launch in early 2027.
- UAE marketing authorization: In July 2026, distribution partner Pharmalink received product marketing authorization approval in the United Arab Emirates for TESTYRA (TLANDO), with a launch planned for early 2027.
Lipocine Reports Q3 2026 Results: Revenue Surge and Pipeline Milestones
According to the filing, Lipocine Inc. (NASDAQ:LPCN) reported total revenue of $2.3 million for the quarter ended September 30, 2026, a significant increase from $115,000 in the same period of 2025. The company disclosed that Q3 2026 revenue comprised license and collaboration revenue of $2.1 million and royalty revenue from TLANDO sales of $190,000, while Q3 2025 revenue consisted entirely of TLANDO royalties.
Research and development expenses were $2.1 million for the quarter ended September 30, 2026, down from $2.7 million in Q3 2025. The filing attributed the decrease primarily to lower costs related to the LPCN 2401 study, which was placed on hold in 2025, and lower LPCN 1154 clinical costs compared to the prior Phase 3 study period, partially offset by higher personnel costs. General and administrative expenses increased to $1.1 million from $0.8 million in Q3 2025, with the company citing higher personnel costs and higher legal fees related to protecting intellectual property and promoting its corporate strategy.
For the nine months ended September 30, 2026, Lipocine reported a net loss of $7.0 million, or ($0.90) per diluted share, compared to a net loss of $7.3 million, or ($1.35) per diluted share, for the same period in 2025. The company also disclosed that as of November 4, 2026, unrestricted cash, cash equivalents, and marketable investment securities were approximately $28.5 million (unaudited). On the pipeline front, the filing noted that FDA feedback acknowledged the NDA submission package for LPCN 1154 "appears complete to support 505(b)(2) NDA submission with the exception of the need for a single positive and well controlled Phase 3 trial," which the BLOOM study is designed to provide.
What Was Disclosed
Lipocine disclosed Q3 and nine-month 2026 financial results, including a narrowed quarterly net loss, a substantial revenue increase driven by license and collaboration income, cash position details, and pipeline updates covering LPCN 1154, TLANDO regulatory approvals in Canada and the UAE, and other development programs.



Please wait processing your request...